Cancer Research

Papers
(The H4-Index of Cancer Research is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Abstract P1-13-04: Evaluation of the impact Vitamin D and Calcium supplementation on bone mineral density in breast cancer patients using or not taking Aromatase Inhibitors: 5-year follow-up363
Abstract P4-12-09: Implications of protocol modifications and treatment delays for breast cancer patient experiences during Covid-19174
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer167
Abstract OT1-05-01: Glycoprotein 88 (GP-88) serum levels as a marker of response to therapy in patients with metastatic breast cancer155
Abstract 1013: Mechanistic role of nelfinavir as drug-repurposing strategy against high-grade serous ovarian cancer152
Abstract P3-19-16: Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated152
Abstract 1151: Targeting castration-resistant prostate cancer using mesenchymal stem cell exosomes for therapeutic microRNA let-7c delivery140
Abstract 1001: Treatment of RB1-intact cancers with CDK4/6 inhibitor combination therapy139
Abstract 2916: Characterization of a mouse model of leptomeningeal melanocytic disease134
Abstract 2884: Wnt11 dictates the patterns and latency of pulmonary micrometastatic disease in pancreatic cancer130
Abstract 2575: Intermittent calorie restriction reverses the adverse effects of obesity and advanced age on tumor growth in a mouse model of breast cancer126
Abstract 1221: The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications124
Abstract 1235: Selective androgen receptor degraders for the treatment of androgen receptor-positive, triple-negative breast cancer123
Abstract 2650: Angiogenic inhibitors reduce mycosis fungoides cell survival and enhance cell death121
Abstract 2945: Novel engineered B-NDG B2M/KO mice plus and steroid treated B-NDG Mice shows delayed GvHD response when engrafted with hPBMC118
Abstract 2481: Time-resolved transcriptome analysis of murine TH-MYCN driven neuroblastoma identifies MEIS2 as early initiating factor and novel core gene regulatory circuitry constituent117
Abstract 2969: Impact of baseline culture condition on the growth and treatment response of mouse derived cancer organoids114
Abstract 2648: A dual functional agent inhibits the angiogenesis and DNA synthesis resulting in the growth suppression of consensus molecular subtypes 1 and 4 in colorectal cancer xenografts113
Abstract 2735: Clinical significance of CD4+CD7−helper T-cells and tumoral CD7 expression in colorectal cancer109
Abstract 2957: A novel circulating tumor DNA (ctDNA) assay enables monitoring of disease progression and treatment response in disseminated preclinical hematologic cancer models106
Abstract 2807: Variations in glycolytic activity of HCC subtypes as monitored by in vivo h 13C MRI104
Abstract 2951: Anti-GCGR in vivo efficacy evaluated in a novel humanized B-hGCGR mouse model103
Abstract 2574: Collagen density and obesity promote mammary gland inflammation101
Abstract 317: Berberine-mediated reprogramming of the inflammatory environment in anaplastic thyroid cancer101
Abstract 3192: PD-L1 is an independent prognostic marker in Middle Eastern PTC and its expression is upregulated by BRAFV600E mutation100
Abstract 525: Novel DARPin multi-specific T-cell engager with an improved therapeutic window to overcome dose limiting toxicities in AML therapies100
Abstract 322: Protein expression shift and potential diagnostic markers through proteomics profiling of A549 lung cancer cells97
Abstract 324: Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600E mutant glioma97
Abstract 375: High tumor mutation burden predicts unfavorable clinical outcome in EGFR-mutated lung adenocarcinoma treated with targeted therapy96
Abstract 433: Clinical validation of a Dickkopf-1 (DKK1) chromogenic in-situ hybridization (CISH) assay for manual and image-analysis assisted pathologist interpretation95
Abstract 1545: Development of FGFR4-targeted chimeric antigen receptors (CARs) for the treatment of rhabdomyosarcoma89
Abstract 184: The utility of deep metric learning for breast cancer identification on mammographic images89
Abstract 1406: FOXC1 induces cisplatin resistance through enhancer activation in bladder cancer87
Abstract 1366: Integrated population modeling of loncastuximab tesirine (Lonca) exposure in B-cell non-Hodgkin lymphoma (B-NHL)86
Abstract 1381: Impact of PI3K/mTOR inhibitors on the development of taxane resistance85
Abstract 1305: Classification of cell morphology using machine learning and label-free live-cell imaging85
Abstract 1327: Role of intra-tumoral bacteria in EGFR-tyrosine kinase inhibitor resistance83
Abstract 1790: BO-112 as a modifier of the tumor microenvironment for liver metastases82
Abstract 1430: In vivo PoC study and design for Phase I clinical study of SJP1604, a nucleolin-targeted therapeutic agent to treat entire population of relapsed/refractory acute myeloid leukemi79
Abstract 1479: Pan-cancer efficacy of BRAF and/or MEK inhibitors in BRAF V600-mutant multiple non-melanoma cancers: A clinico-genomic study78
Abstract 133: Skeletal muscle transcriptome profiling of human pancreatic cancer cachexia: single largest study in cachexia78
Abstract 1896: The genomic features of Chinese cancer patients harboring HLA LOH77
Abstract 1629: IO-202, a first-in-class LILRB4 antagonist antibody, activates dendritic cells and inhibits solid tumor growth in preclinical studies77
Abstract 1634: Siglec-15 knockout inhibits tumor growth in mouse model77
Abstract 1513: A case study investigation into the role of CD4+ tumor-infiltrating lymphocytes in a metastatic melanoma patient with a complete response to adoptive cell therapy76
Abstract 1980: Non-canonical regulation and function of anti-apoptotic protein c-FLIP76
Abstract 1324: Evaluation of KIF14 in a chemotherapeutic resistant breast cancer cell line76
Abstract 1587: Generation and characterization of novel bispecific molecules combining single-chain-CD40L with anti-CEA, anti-CD95L or anti-PD-L1 targeting moieties74
Abstract 1362: Exposure-response (E-R) analysis of efficacy for avelumab as first-line maintenance therapy for urothelial carcinoma in the JAVELIN Bladder 100 study72
Abstract PD13-07: Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative l71
Abstract P5-08-02: MORAb-202, an antibody-drug-conjugate (ADC) targeting folate receptor alpha (FRα), exhibits durable anti-tumor efficacy in PDx models of TNBC69
Abstract P3-20-09: Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response69
Abstract P3-12-20: Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer68
Abstract CT144: Development of GMI-1359, a novel agent targeting tumor-microenvironment cross-talk in bone metastatic cancer68
Abstract P4-01-16: Overcome chemoresistance of triple-negative breast cancer by inhibiting the RNA-binding protein HuR67
Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination Immunotherapy67
Abstract PD3-03: EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression66
Abstract LB071: Tuning the tumor myeloid microenvironment (TME) by targeting TREM2+ tumor-associated macrophages to overcome resistance to immune checkpoint inhibitors66
Abstract OT2-21-01: A randomized, multicenter pragmatic trial comparing bone pain from a single dose of pegfilgrastim to 5 doses of daily filgrastim in breast cancer patients receiving neoadjuvant/adj66
Abstract P4-11-16: Feasibility and patient satisfaction with a smartphone application to improve medication adherence among patients with breast cancer65
Abstract 2126: Therapeutic potential of CPI-020965
Abstract P3-18-14: Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer64
Abstract P4-05-09: Clinicopathologic characteristics and molecular profiling of HER2-low breast cancer: A single academic institution experience64
Abstract 3175: FAT1 and the immunosuppressive milieu in glioblastoma tumors64
Abstract P4-10-10: Effectiveness and feasibility of exercise-oncology programs in breast cancer patients using new technologies adapted to the COVID 19 new normality64
1.0254900455475